444 related articles for article (PubMed ID: 27816190)
1. Targeting the androgen receptor in triple-negative breast cancer.
Gucalp A; Traina TA
Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
3. [Androgen receptors in breast cancer: Expression, value and therapeutic prospects].
Héquet D; Mzoughi S; Rouzier R; Guccione E
Bull Cancer; 2017 Apr; 104(4):363-369. PubMed ID: 28216075
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
5. Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR; Chandler B; Olsen E; Wilder-Romans K; Moubadder L; Liu M; Pesch AM; Zhang A; Ritter C; Ward ST; Santola A; Nyati S; Rae JM; Hayes D; Feng FY; Spratt D; Wahl D; Eisner J; Pierce LJ; Speers C
Front Endocrinol (Lausanne); 2020; 11():35. PubMed ID: 32117061
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
10. [Androgen receptor-positive triple negative breast cancer: From biology to therapy].
Grellety T
Bull Cancer; 2020 Apr; 107(4):506-516. PubMed ID: 32145961
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.
Caiazza F; Murray A; Madden SF; Synnott NC; Ryan EJ; O'Donovan N; Crown J; Duffy MJ
Endocr Relat Cancer; 2016 Apr; 23(4):323-34. PubMed ID: 26932782
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
[TBL] [Abstract][Full Text] [Related]
14. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
15. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
[TBL] [Abstract][Full Text] [Related]
16. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment of bicalutamide and curcumin has a strong therapeutic effect on androgen receptor-positive triple-negative breast cancers.
Dong S; Alahari SK
Anticancer Drugs; 2020 Apr; 31(4):359-367. PubMed ID: 31917699
[TBL] [Abstract][Full Text] [Related]
18. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
[TBL] [Abstract][Full Text] [Related]
19. Revising the role of the androgen receptor in breast cancer.
Fioretti FM; Sita-Lumsden A; Bevan CL; Brooke GN
J Mol Endocrinol; 2014 Jun; 52(3):R257-65. PubMed ID: 24740738
[TBL] [Abstract][Full Text] [Related]
20. Triple negative breast cancer: special histological types and emerging therapeutic methods.
Cao L; Niu Y
Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
